PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2010; 5(10): e13406.
Published online 2010 October 20. doi:  10.1371/journal.pone.0013406
PMCID: PMC2958115

Identification of Piwil2-Like (PL2L) Proteins that Promote Tumorigenesis

Sumitra Deb, Editor

Abstract

PIWIL2, a member of PIWI/AGO gene family, is expressed in the germline stem cells (GSCs) of testis for gametogenesis but not in adult somatic and stem cells. It has been implicated to play an important role in tumor development. We have previously reported that precancerous stem cells (pCSCs) constitutively express Piwil2 transcripts to promote their proliferation. Here we show that these transcripts de facto represent Piwil2-like (PL2L) proteins. We have identified several PL2L proteins including PL2L80, PL2L60, PL2L50 and PL2L40, using combined methods of Gene-Exon-Mapping Reverse Transcription Polymerase Chain Reaction (GEM RT-PCR), bioinformatics and a group of novel monoclonal antibodies. Among them, PL2L60 rather than Piwil2 and other PL2L proteins is predominantly expressed in various types of human and mouse tumor cells. It promotes tumor cell survival and proliferation in vitro through up-regulation of Stat3 and Bcl2 gene expressions, the cell cycle entry from G0/1 into S-phase, and the nuclear expression of NF-κB, which contribute to the tumorigenicity of tumor cells in vivo. Consistently, PL2L proteins rather than Piwil2 are predominantly expressed in the cytoplasm or cytoplasm and nucleus of euchromatin-enriched tumor cells in human primary and metastatic cancers, such as breast and cervical cancers. Moreover, nuclear PL2L proteins are always co-expressed with nuclear NF-κB. These results reveal that PL2L60 can coordinate with NF-κB to promote tumorigenesis and might mediate a common pathway for tumor development without tissue restriction. The identification of PL2L proteins provides a novel insight into the mechanisms of cancer development as well as a novel bridge linking cancer diagnostics and anticancer drug development.

Introduction

A major obstacle for cure of cancer is that we still do not sufficiently understand how a cancer is initiated and progressed, despite the revived cancer stem cell (CSC) hypothesis [1], [2], [3], [4]. Recently we have identified and established several clonal precancerous stem cell (pCSC) lines (Lin-CD44+CD24-) from murine lymphoma, which have the potential of both benign and malignant differentiation, depending on environmental cues [1], [5], [6]. The identification of pCSCs suggests that pCSCs are a precursor of CSCs [1]. Both pCSCs and CSCs, which are considered to represent two developing stages of tumor stem cells (TSCs) [1], [3], [4], can serve as tumor vasculogenic progenitor cells (TVPCs) [6], [7]. The existence of pCSCs has been functionally and clinically verified in the murine mammary carcinoma [8] and human leukemia [9] as well as intestinal precancerous lesions [10], [11], [12]. Through the study of pCSCs, we have found that the transcripts of germline stem cell (GSC) gene PIWIL2 are constantly expressed in pCSC lines, but not in normal bone-marrow (BM)-derived stem/progenitor cells [5], suggesting that it may play an important role in TSC development [1], [3], [4].

The PIWIL2 (piwi-like 2: alias hili in humans or mili in mouse) is a member of PIWI/AGO gene family [13], located at human chromosome 8 and mouse chromosome 14, respectively, with 23 exons coding 973 amino acids (110 kDa of MW) with about 88.77% homologous between humans and mice in gene sequence (http://www.genecards.org/cgi-bin/carddisp.pl?gene=PIWIL2). PIWI/AGO proteins contain Piwi and PAZ domains, having multiple biological functions on GSC self-renewal, cell cycling, RNA interference (RNAi), epigenetic modulation, and chromatin remodeling in various organisms [14], [15], [16]. Four members of PIWI or AGO subfamily have been identified in human genome (Piwil1, 2, 3 and 4; and AGO1, 2, 3 and 4) [13]. All the members of PIWI subfamily are mainly expressed in the testis or embryonic tissues, and are essential for stem cell self-renewal such as in Drosophila [17] and gametogenesis in mammals [18], [19], [20]. The AGO subfamily is ubiquitously expressed in the embryonic and adult tissues [13], [18], [21], [22], mediating RNAi via forming two types of RNAi complex: RNA-induced gene silencing complex (RISC) and RNA-induced initiation of transcriptional gene silencing (RITS) complex [14], [23], [24], [25], [26], [27]. The former mediates post-transcriptional gene silencing through activating RNase activity and cleaving the RNA [24], [28], [29], [30], and the latter is required for transcriptional gene silencing and/or chromatin remodeling [15], [16], [26], [31].

Among PIWI subfamily members, PIWIL2 might play unique roles in tumor development, although the underlying mechanisms are largely unknown [1], [3], [4], [5], [21]. The PIWIL2 is silenced in adult somatic and stem cells [1], [5], [21], but is widely expressed in various types of cancers, including hematopoietic, cervical and breast cancers [5], [21], [32], [33], [34], [35]. Especially, it is stably expressed in pCSCs [1], [5], suggesting that it might play an important role in tumor initiation and progression. Other members of PIWI subfamily might also play roles in tumorigenesis [36], [37]. Recently, Piwil2 has been found to bind a novel class of small (26–30 nt) RNA, which is named as piwi-interacting RNA (piRNA) or repeat-associated small interfering RNAs (rasiRNAs), in mammal testis [38], [39], [40], [41], [42], [43]. It may silence selfish genetic elements, such as retrotransposons, in the GSCs of testis [39], [43], [44]. Moreover, Piwi proteins also mediate epigenetic activation through promoting euchromatin histone modifications and piRNA transcription in subtelomeric heterochromatin in Drosophila [15], [16], suggesting that Piwil2 may regulate tumor development epigenetically.

We have reported that knockdown of “Piwil2 mRNAs” by Piwil2-specific small interference RNAs (siRNAs) significantly reduced murine pCSC expansion in vitro [5]. However, overexpression of Piwil2 gene in BM cells cultured in the XLCM-conditioned medium induced proliferation of the stem/progenitor cells, changes in cell morphology, and formation of embryonic body (EB)-like colonies, followed by apoptosis [5]. We refer to this phenomenon as the proliferation- or transformation-associated cell death (PACD or TACD), characterized by a timing difference between cell proliferation and apoptosis. This delayed cell death induced by exogenous Piwil2 is in contrast to the growth-promoting or anti-apoptotic role of “Piwil2” that is spontaneously expressed in pCSCs [5] or transiently expressed in NIH-3T3 cells [21]. The contradictory observations suggest that Piwil2 either plays a distinct role in pCSCs versus normal stem/progenitor cells or itself is expressed in a different form.

In this study, we demonstrate that the “Piwil2” transcripts expressed in pCSCs represent the transcripts of Piwil2-like (PL2L) genes rather than Piwil2, as revealed by Piwil2-specific Gene-Exon-Mapping Reverse Transcription Polymerase Chain Reaction (GEM RT-PCR) in combination with bioinformatics and biochemical analysis. Using monoclonal antibodies (mAbs), which were generated in our laboratory and specific for a peptide common to PIWIL2 and PL2L proteins of humans and mice, we reveal that the PL2L genes encode at least four proteins, including PL2L80, PL2L60, PL2L50 and PL2L40. Among them, PL2L60 is predominantly expressed in pCSCs and various types of tumor cell lines, including those derived from the blood, skin, soft tissues, kidney, brain, breast, liver, pancreas, cervix, colon, ovarian, liver and lung of humans and mice. PL2L60 appears to support cell survival and proliferation through up-regulating Stat-3 and Bcl-2 genes, promoting transition of G0/1 to S-phase of cell cycle and enhancing nuclear expression of RelA, a member of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) family. Overexpression of PL2L60 in human breast cancer cell lines promoted their tumorigenesis at the initial or latent stage of xenograft tumor formation. While PL2L proteins can be widely detected in the euchromatin-enriched proliferating tumor cells in primary and metastatic cancers, such as breast and cervical cancers, PIWIL2 was detected mainly in apoptotic or apoptosing cells. Moreover, PL2L proteins are always co-expressed with NF-κB/RelA in the cytoplasm or nucleus, suggesting that PL2L60, in cooperation with NF-κB, may play important but opposite roles to Piwil2 in tumor development. The identification of PL2L proteins provides a novel insight into the mechanisms of cancer development as well as a novel target bridging cancer diagnostics and anticancer drug development.

Results

Precancerous stem cells do not express full length Piwil2 transcripts

In order to solve the contradictory function between the spontaneously expressed Piwil2 in pCSCs and transduced-Piwil2 in normal stem/progenitor cells [5], we investigated whether the difference is caused by the dose of Piwil2 gene or its variants in these cells. We designed a pair of primers to detect full length Piwil2 transcripts in pCSCs by RT-PCR. The primers could amplify full length Piwil2 transcripts in the testis, but unexpectedly, failed to do so in the murine pCSC lines, including 2C4, 3B5C and 3B6C [5] (Fig. 1A). The result suggested that a Piwil2 gene variant(s) might be expressed in the pCSCs. To estimate the length of Piwil2 transcripts [5], we performed GEM RT-PCR, which could detect both full length Piwil2 transcripts and its potential variants. We designed four pairs of Piwil2-specific primers which cover full length Piwil2 transcript containing 23 exons. Each primer pair spanned at least one intron (Fig. 1B & supplementary Table S1). The upstream of each pair of primers overlapped with the downstream of the previous one. As shown in Figure 1C, exons 1–7 were amplified neither in 3 clonal pCSC lines (2C4, 3B5C and 3B6C) [5] nor in a hematopoietic cancer stem cell (CSC) line (clone 326T) [1]. In addition, exons 21–23 were also not amplified in pCSCs (Fig. 1C). This was not caused by the inability of these two primers to amplify corresponding exons, because each of the four primer pairs was able to amplify corresponding Piwil2 exons in the same sample of murine testis used in Fig. 1A (Fig. 1C & D). As expected, no Piwil2 transcripts were detected from the freshly isolated splenocytes (Fig. 1C). In agreement with the previous report [5], the primers Pmili, which is specific for exons 18–21 (E18-21) of murine Piwil2 and was routinely used in our laboratory for the detection of “Piwil2 mRNA in pCSCs and other tumor cell lines, reproducibly amplified the “Piwil2 mRNA in the pCSC lines (Fig. 1C). These results suggest that the gene products amplified by the primers Pmili may not necessarily represent full length Piwil2 transcripts and that “Piwil2” mRNAs detected by this primer pair in the pCSCs might represent a Piwil2 variant(s), likely truncated at the 5′-end (Fig. 1D).

Figure 1
pCSC lines do not express full length Piwil2 transcripts.

Identification of Piwil2-like (PL2L) genes and proteins in the testis and tumor cell lines but not in normal tissues

Current data have shown that human PIWIL2 gene containing 23 exons is significantly larger than an average human gene (Fig. 2A). Different exon usage often leads to production of spliced mRNA variants, and differential promoter utilization inside a gene often results in the formation of related but functionally distinct proteins. These mechanisms greatly expand the coding capacity of a gene. Therefore, we reasoned that PIWIL2 gene might use these mechanisms to generate Piwil2 variants in particular conditions. To identify potential Piwil2 variants, we first used the software Gene2Promoter from Genomatix Software Inc. (Ann Arbor, MI) to analyze human and mouse PIWIL2 genes in order to find potential promoters inside these genes. The results showed that there are six potential promoters inside the PIWIL2 gene of humans or mice (Fig. 2A). Among these promoters, five promoters can be identified as the transcriptional initiators of PIWIL2, PL2L60, PL2L50, PL2L40 and PL2L42, respectively, in humans or mice (Fig. 2A). The promoter of PL2L60 is located in the region that starts from inside the intron 10 and includes most sequence of Exon 11 (Fig. 2A). This promoter initiates the transcription of PL2L60 mRNA that can be translated into 60 kDa protein PL2L60, in which PAZ domain is defective (Fig. 2B & 2C). The predicted PL2L60 mRNA is confirmed by transcribed sequence AK027497 from Genbank. The promoter of PL2L50 is located inside the intron 13 (Fig. 2A), which transcribe PL2L50 mRNA covering exons 14 to 23 (Fig. 2B) and its protein product contains Piwi domain truncated at N-terminus (Fig. 2C). The predicted PL2L50 is confirmed by transcribed sequence AK163647 (murine) from Genbank. The promoter of PL2L42 is located at the region that starts from inside the intron 14 and includes entire Exon 15 (Fig. 2A). This promoter initiates the transcription of PL2L42 mRNA that might be translated into a 42 kDa protein PL2L42, which is only a part of Piwi domain truncated at N-terminus (Fig. 2B & 2C). The predicted PL2L42 mRNA is supported by transcribed sequence AK001213 from Genbank. The promoter of PL2L40 is located inside the intron 12 (Fig. 2A). It initiates the transcription of PL2L40 gene, which contains exons from 13 to 20 and two additional exons within the intron between exons 20 and 21. The PL2L40 contains a C-terminus truncated Piwi domain (Fig. 2B & 2C). The predicted PL2L40 mRNA is confirmed by transcribed sequence XM_942053 in Genbank. These predicted mRNAs are all truncated at the 5′-end, resulting in a defect or absence of PAZ domain (Fig. 2C). The mRNA sequences of human PL2L60, PL2L50, PL2L40 and PL2L60 and murine PL2L50 can be found in Genbank.

Figure 2
Diagram of PIWIL2 and PL2L genes as well as their transcriptional and translational products.

To verify the protein expression of these PL2L genes in humans and mice, we designed a C-terminal Piwil2 peptide with amino acid sequence (15-mers) between PAZ and Piwi domains, which is shared by Piwil2 and putative PL2L proteins as well as homologous between the humans and mice. We immunized two rabbits with the peptide to generate polyclonal antibody (pAb) specific for Piwil2 and PL2L proteins. We obtained a high titer of peptide-specific rabbit pAb from one of the rabbits (RB9926), which was purified by the specific peptide-affinity chromatography and further characterized by Western-blot. As shown in Fig. 3A, the purified pAb can recognize a number of protein bands with estimated molecular weight (MW) of 110, 80, 60, and 50 kDa in both murine testicular cell lysates (Fig. 3A) and human tumor cell lysates (HeLa) (Fig. 3B). These proteins are Piwil2-peptide specific, because 110 and 50 kDa protein bands were not detected in the testicular cell lysates of mili−/− mice [18] and the 80 and 60 kDa protein bands were greatly reduced compared to wild-type (wt) mice (Fig. 3A). Consistently the same protein bands in the human tumor cell lysates were almost completely blocked by Piwil2 peptides, which were used as immunogens (Fig. 3B). The results suggested that the Piwil2-specific polyclonal antibody at least recognize three Piwil2-like proteins (PL2L80, PL2L60, and PL2L50). Among them, PL2L80 could not be predicted from NCBI GeneBank or Genomatix database (http://www.genomatix.de/). Incomplete disruption of PL2L80 and PL2L60 proteins in the mili−/− testis appeared to be associated with the expression of transcripts covering Piwil2 exons from 6 to 23, which were not abrogated at all in mili−/− testis, as well as with the low level expression of Piwil2 exons from 1 to 7 in mili−/− mice, as demonstrated by Piwil2-specific GEM RT-PCR (Fig. 3C), although the underlying mechanism is not yet clear. In the mili−/− mice, Piwil2 was disrupted via homologous recombination with the 5.2-kb BamHI fragment encompassing from exon 2 to exon 5 in the pPNT vector with a neomycin resistance cassette [18]. Thus, the transcripts of PL2L genes or transcripts of Piwil2 truncated at 5′ end, which were controlled by other independent promoters, were not completely suppressed in mili−/− testis (Fig. 2). The results suggest that whole Piwil2 protein, but not its variants such as PL2L80 and PL2L60, are completely disrupted in the mili−/− mice.

Figure 3
Identification and characterization of PL2L proteins of humans and mice.

Although the gene sequence of PL2L80 was not found in the gene banks so far, we have successfully cloned PL2L80, which appears to utilize the same promoter as full length PIWIL2 does (unpublished data). Characterization of PL2L80 gene is ongoing in our laboratory.

PL2L60 is predominantly expressed in precancerous stem cells

To determine the expression profiles of Piwil2 and PL2L proteins in pCSCs, the pCSC lines (clone 2C4, 3B5C and 3B6C) were analyzed by Western-blotting. As shown in Fig. 4, each pCSC line expressed a high level of PL2L60, but little PL2L50 and no Piwil2. As a negative control, no PL2L60 was detected in splenocytes (Fig. 4A & B). Moreover, no Piwil2 and PL2L proteins were detected in other tissues of normal mice, either by Western-blotting or RT-PCR (supplementary Fig. S1), consistently with others' reports [13], [18], [21]. Interestingly, the level of PL2L60 protein in the pCSCs was 3.5~7.0 times more than that in 326T cells, a hematopoietic CSC line that was established and cloned in our laboratory ([1] & unpublished data). Compared to the background in normal splenocytes, PL2L60 protein was dramatically increased by 56.6 to 120 times in the pCSCs but only by 17.2 times in 326T cells (Fig. 4B). Interestingly, 326T cells were more susceptible to apoptosis compared to 2C4, 3B5C and 3B6C cells when they were cultured in vitro (Fig. 4C), probably associated with the lower level of PL2L60. In parallel, more transcripts from Piwil2 exon 18–21, amplified by Pmili, were detected in pCSC lines than in 326T cells, but not in normal splenocytes (Fig. 1C: Pmili: E18-21). These results implicated that “Piwil2” transcripts expressed in pCSCs [5] de facto represent the transcripts of PL2L60.

Figure 4
PL2L60 rather than Piwil2 is predominantly and stably expressed in pCSC lines.

PL2L60 up-regulates Stat-3 and Bcl-2 genes and promotes pCSC expansion

Because PL2L60 was predominantly expressed in the pCSCs (2C4, 3B5C and 3B6C) (Fig. 4), we reasoned that PL2L60 is associated with pCSC expansion in vitro. In order to verify the hypothesis, we knocked down PL2L60 mRNAs in pCSCs (clone 2C4) by transfection with siRNAs targeting exon 11 of Piwil2 transcripts. As a result, PL2L60 expression was reduced at both transcriptional and translational levels in the siRNA-transfected cells, as compared to the controls including the cells transfected with scrambled siRNA (scRNA), mock transfected and un-transfected (Fig. 5A, B & C). Correspondingly, pCSC expansion was also significantly suppressed in the siRNA-transfected pCSCs (Fig. 5D). The reduced pCSC expansion was associated with down-regulation of the transcripts of Stat-3 and Bcl-2 genes but not Bcl-XL gene in the pCSCs (Fig. 5E & F). The Piwil2 exon 11 is located within the putative open reading frame of PL2L60 gene (Fig. 2A). Consistently, the transcriptional products of both E6-14 and E18-21 were also significantly reduced in the pCSCs transfected with siRNA targeting exon 11 (Fig. 5C). The results reveal that the “Piwil2” mRNAs that was previously reported to be stably expressed in pCSC lines [5] de facto represent the mRNAs of PL2L60 gene, which can support pCSC expansion in vitro through promoting Stat-3/Bcl-2 pathway.

Figure 5
PL2L60 promotes pCSC expansion in vitro through up-regulation of Stat3 and Bcl2 gene expressions.

PL2L60 is widely expressed in various types of human cancer cells

To determine whether PL2L60 is also expressed in human tumors, we examined PL2L60 expression in various types of human cancer cell lines. As shown in Fig. 6A, PL2L60 was predominantly expressed in cervical (HeLa) and breast cancer cell lines (Fig. 6A). Among the breast cancer cell lines, MCF7 line that usually grew slower in culture than MDA-MB-231 and MDA-MB-468 (not shown) expressed lower level of PL2L60 proteins (Fig. 6B). In contrast, long-term cultured primary human dermal fibroblasts (HDF) expressed little PL2L60 proteins (Fig. 6A & B). In addition to cervical and breast cancer cell lines, PL2L60 proteins were also predominantly detected in other tumor cell lines derived from the tumors of blood, skin, soft tissues, kidney, brain, breast, liver, pancreas, cervix, colon, ovarian, liver and lung. The tumor types involved include leukemia, lymphoma, adenoma, adenocarcinoma, carcinoma, melanoma, sarcoma, neuroblastoma, hepatoma, insulinoma and endothelioma (supplementary Fig. S2 & Table S2). The results suggest that PL2L60 is widely expressed in various types of cancers without restrictions of tissue origin and tumor types. In addition, Piwil2, PL2L80 and PL2L50 were also detected in low levels or not detected at all in these lines with great variation between lines as well as between individual experiments (Fig. 3 & Fig. S2). The results suggest that the levels of PL2L proteins expression in the cancer cell lines might be affected by culture conditions, but PL2L60 is always predominantly expressed.

Figure 6
PL2L60 is predominantly expressed in human tumor cells, promoting their expansion in vitro.

PL2L60 promoting tumorigenesis is associated with increased nuclear NF-κB expression

Since PL2L60 could promote pCSC proliferation in vitro ([5] & Fig. 5), we examined whether it also promoted human tumor cell proliferation in vitro through knocking down PL2L60 mRNAs in human breast cancer cell lines (MDA-MB-231) (Fig. 6C). As a result, the proliferation of the MDA-MB-231 cells was also significantly inhibited after knocking down PL2L60 mRNAs (Fig. 6D), confirming that PL2L60, like in murine pCSCs, can also support cancer cell proliferation in vitro. To further confirm the function, we generated stable PL2L60-expressing cancer cell lines by transducing human PL2L60 gene into MDA-MB-231 cells (Fig. 7 & Fig. S3). The PL2L60-transduced cells demonstrated significant increase in the entry of cycling cells from G0/1 into S-phase, as compared to GFP-transduced control cells. This was consistent with increased cell expansion in vitro (Fig. 7A & B). Moreover, the increased cell expansion was associated with enhanced expression of nuclear NF-κB (RelA/p65), a protein complex that controls the transcription of genes including those responsible for cancer cell survival and proliferation [45], [46], [47] (Fig. 7C). While NF-κB was strongly detected in the cytoplasm but weakly in the nucleus of the GFP-transduced cells, almost all of the PL2L60-transduced cells expressed a high level of NF-κB in both cytoplasm and nucleus. The cell size of PL2L60-transduced cells was obviously increased compared to that of GFP-transduced cells, suggesting an enhanced cell growth (Fig. 7C). It should be noted that <1% of cells expressed stronger cytoplasmic and nuclear NF-κB in both samples of PL2L60-transduced and GFP-transduced cells (Fig. 7C: arrows). The significance of the rare population is warranted to be investigated further.

Figure 7
PL2L60 promoting tumorigenesis of human cancer cells is associated with the enhanced cell cycle transition from G0/1 to S phase and increased nuclear NF-κB expression.

To determine the tumorigenic capacity of the PL2L60-transduced tumor cell line, we transplanted PL2L60- and GFP-transduced MDA-MB-231 cells into CB17 SCID mice, respectively. The tumor nodules formed by PL2L60-transduced cells were palpable as early as one week after transplantation, whereas GFP-transduced control cells did not form palpable tumor nodules at this time (Fig. 7D & E). Interestingly, the tumor nodules were regressed three weeks later, but recurred with a tumor growth rate comparable to that of GFP-transduced cells (Fig. 7D & E). At the end of experiments, both PL2L60- and GFP-transduced tumors were GFP-positive as detected by live imaging (not shown). The result suggests that PL2L60 could promote tumorigenesis at the initiating stage of xenograft tumor formation.

Piwil2 and PL2L proteins are differentially expressed in human primary and metastatic cancers

To determine whether PL2L60 was also predominantly expressed in native cancers in addition to tumor cell lines, we attempted to generate murine monoclonal antibody (mAb) to Piwil2 and PL2L60 or other PL2L proteins. Because polyclonal Piwil2-peptide specific antibody recognizes both Piwil2 and PL2L proteins (Fig. 3A & B), we used the same strategy to generate mAbs to Piwil2 and PL2L proteins. Although we could not obtain a mAb exclusively detecting PL2L60, we have established one mAb specifically recognizing Piwil2 (clone Kao1) and two mAbs recognizing both Piwil2 and PL2L proteins (clones Kao2 and Kao3). As shown in Fig. 8A, the mAb Kao1 reacted with ~110 kDa proteins in the murine testis, but not any proteins in the cancer cell lysates from human colorectal cancer cell line SW480 [48]. In contrast, mAbs Kao2 and Kao3 reacted strongly with ~110 kDa and~40 kDa proteins in the murine testis and ~60 kDa and ~50 kDa proteins in the cancer cell lysates. In addition, mAbs Kao2 and Kao3 reacted weakly with ~80 kDa, ~60 kDa and ~50 kDa proteins in the testis of mice, and ~110 kDa and ~80 kDa proteins of the cancer cell lysates (Fig. 8A). The different strength of the proteins bands likely reflected different levels of the proteins in the murine testis and human cancer cell line. Thus, mAbs Kao2 and Kao3 can recognize Piwil2, PL2L80, PL2L60, PL2L50 and PL2L40, similarly to the proteins recognized by Piwil2 peptide-specific pAb, except for PL2L40 (Fig. 3B). Again, PL2L60 was predominantly expressed in the colon cancer cell lines as detected by mAbs Kao2 and Kao3 (Fig. 8A).

Figure 8
PL2L proteins rather than Piwil2 are predominantly expressed in human primary and metastatic cancers in association with NF-κB.

Then, we used the mAbs Kao1 and Kao2/3 (thereafter referred to as Kao2) to examine the expression of Piwil2 and PL2L proteins in the tissue microarray (TMA) cores of human breast (n = 300) and cervical cancers (n = 100) or in some tissues sections of the cancers. As shown in Fig. 8, only 1.67% of breast cancer TMA cores (5/300) and 3% of cervical TMA cores (3/100) were stained by mAb Kao1 (Fig. 8E), in which Piwil2 (Kao1)-expressing cells were usually low in frequency (Fig. 8B); in contrast, all TMA cores of cervical and breast cancers were stained by mAb Kao2 (Fig. 8B). However, the frequency of the positively stained cells varied between individuals (Fig. 8 & not shown). While Kao1+ cells displayed condensed nuclei, an apparent feature of apoptosing or apoptotic cells in morphology (Fig. 8B1 & B3), the Kao2+ cells exhibited large nuclei enriched with euchromatin, a feature of cell proliferation (Fig. 8B2 & B4). The tumor cells with a high level of heterochromatin were either negative or faintly positive for PL2L proteins (Fig. 8B2, compare the nuclei between Kao2+ and Kao2- cells in the inset). In addition, PL2L proteins were detected by Kao2 mAb mainly in cytoplasm (pattern: C) or in both cytoplasm and nucleus (pattern: C-N) (Fig. 8B2, pattern C indicated by red arrow; and pattern C-N indicated by green arrows). In the metastatic cancer, all tumor cells were Kao2-positive, whereas only a few of apoptotic or apoptosing Kao1+ cells were occasionally detected regardless of the locations (lymph nodes or connective tissue) of tumor cells (Fig. 8C). The results suggest that Piwil2 is mainly expressed in apoptotic or apoptosing tumor cells, whereas PL2L proteins were expressed in euchromatin-enriched proliferating and metastatic cancer cells. Thus, Kao2 and Kao3 mAbs could be used for detection of both primary and metastatic cancers.

Because PL2L60 could promote breast cancer cell proliferation in vitro, and overexpression of PL2L60 was associated with increased nuclear NF-κB expression in tumor cell lines (Fig. 7), we further investigated whether the expression of PL2L60 or PL2L proteins was also associated with NF-κB expression in primary and metastatic cancers. Breast cancer tissue sections were co-stained with murine mAb (Kao2) to PL2L proteins and rabbit mAb to RelA/p65, a subunit of NF-κB. Both PL2L proteins and p65 were detected in the cytoplasm and nucleus of primary (Fig. 8D) and metastatic cancers (not shown). Almost all the Kao2+ cells were co-stained by mAb to p65 regardless of C or C-N patterns (Fig. 8D3); although the ratio of Kao2 (brown) to p65 (pink) was individually different (not shown). Importantly, nuclear NF-κB expression appeared to be dependent on nuclear PL2L proteins expression, because p65 or PL2L proteins alone were not detected in the nucleus of tumor cells (Fig. 8D4; yellow arrows indicate double stained nuclei), despite the fact that variable levels of nuclear p65 were detected in a few nuclei of infiltrated inflammatory cells (Fig. 8D4; green arrows). Nuclear Kao2+p65+ cells were about 24 ±10.58% among all Kao2+p65+ tumor cells (ranging from 9.09% to 42.42% per tumor nest; n = 16). Given the roles of NF-κB in tumorigenesis [45], [46], [47], the results suggest that nuclear Kao2+p65+ tumor cells might play a critical role in tumor development.

Discussion

We and others have reported that Piwil2 proteins or Piwil2 transcripts were detected in various types of cancers or cancer cell lines [1], [3], [5], [21], [34], [35], [49], [50]. While exploring the mechanism underlying Piwil2-mediated tumor development, we found by GEM RT-PCR that the “Piwil2” transcripts expressed in the murine pCSCs were truncated at 5′-end and absent of first 6 exons of Piwil2. Through bioinformatics analysis of human and mouse PIWIL2 gene, we found several potential 5′-end truncated variants of PIWIL2, called Piwil2-like (PL2L) genes. Based on the information, we generated novel polyclonal and then monoclonal antibodies to a peptide shared by Piwil2 and PL2L proteins of humans and mice and identified four PL2L proteins, including PL2L80, PL2L60, PL2L50, and PL2L40, in the testis and cancer cell lines of humans and mice. Interestingly, PL2L60, instead of Piwil2 and other PL2L proteins, were predominantly expressed in pCSCs and various types of human and mouse tumor cell lines, including those of leukemia, lymphoma, adenoma, adenocarcinoma, carcinoma, melanoma, sarcoma, neuroblastoma, hepatoma, which were derived from various types of organs and tissues such as blood, skin, soft tissues, kidney, brain, breast, liver, pancreas, cervix, colon, ovarian, liver and/or lung. The finding strongly suggests that PL2L60 is widely expressed in tumor cells regardless of tumor types and tissue origins. Consistent with the observations from cancer cell lines, PL2L proteins were also predominantly expressed in primary and metastatic cancers; whereas Piwil2 were essentially undetectable except in some apoptotic or apoptosing cells. Because PL2L60 is predominantly expressed in cancer cell lines, it is likely that PL2L proteins detected by the mAbs Kao2/3 in primary and metastatic cancers actually are PL2L60. The results reveal that PL2L60 rather than Piwil2 are constitutively and widely expressed in various types of cancers without the restriction of tissue origin. The notion is also supported by the fact that Piwil2 transcripts were undetectable in the bladder cancers by real-time RT-PCR with the primers amplifying first 6 exons of PIWIL2 [51], which are absent in PL2L genes. Therefore, the “Piwil2” transcripts amplified by primers within PL2L genes and the translated proteins detected by mAbs Kao2/3, de facto represent PL2L genes and PL2L proteins in cancer cell lines or in the tissues of primary and metastatic cancers. The mAb Kao1 can be used to specifically identify Piwil2 and distinguish what are detected by Kao2/3 from Piwil2. It should be noted that almost all metastatic cancer cells were detected by mAb Kao2, suggesting that PL2L proteins are potentially a specific marker for metastatic cancers. Taken together, we have identified a novel protein PL2L60, which is widely expressed in various types of cancers and might have the potential to be used as a common cancer biomarker. Other PL2L proteins such as PL2L80, PL2L50 and PL2L40 need to be characterized further.

Obviously, PL2L60 is not limited to be expressed in pCSCs [5]. It was also detected in various types of cancer cell lines. Knockdown of PL2L60 mRNAs in murine pCSCs or human breast cancer cells significantly suppressed their expansion in vitro. In agreement, over-expression of PL2L60 in the breast cancer cell lines led to their increased expansion in vitro. The mechanisms underlying the increased expansion appear to be mediated by reduced programmed cell death (PCD) because of enhanced expression of Bcl-2 and Stat3 genes and promoted G0/1 → S-phase in cell cycle by PL2L60. This is further supported by the increased expression of nuclear NF-κB in the PL2L60-transduced cell lines. NF-κB is a ubiquitous transcription factor that controls the expression of genes involved in immune response, cell survival, apoptosis, and cell cycle. Given the fact that NF-κB is inactivated in cytosol complexed with the inhibitory protein IκBα but activated by ubiquitination of IκBα, shuttling to nucleus, only is nuclear NF-κB considered to be functional [45], [46]. Nuclear translocation of NF-κB may up-regulate prosurvival factor Bcl-2 in tumor cells, as observed in human hepatoma cells [52]. Thus, the increased nuclear NF-κB expression in the nuclei of PL2L60-transduced cells may lead to increased cell expansion through up-regulating cell survival genes Stat-3 and Bcl-2 and promoting cell cycling (Fig. 9).

Figure 9
The hypothetical mechanisms underlying PL2L60 promoting tumorigenesis.

The in vitro findings are supported by in vivo observations that PL2L60-transduced human breast cancer cells formed palpable tumor nodules rapidly within first few weeks after transplanted into CB17 SCID mice, while GFP-transduced cells were at the latent period of tumorigenesis. Usually it takes at least two to three months (latent phase) to form palpable xenograft tumors, which are supposed to be mediated by rare numbers of CSCs in the context of freshly isolated tumor cells or tumor cell lines ([1], [4], [53] & unpublished observation). The formation of tumor nodules by PL2L60-transduced cells at the latent phase suggests that they proliferated faster in vivo than GFP-transduced cells did. Moreover in primary and metastatic cancers of humans, the exclusive expression of PL2L60 or PL2L proteins in the euchromatin-enriched tumor cells also suggests that the PL2L60-expressing cells are highly active or proliferative [32], [33], which contributes to enhanced tumor growth.

However, it is puzzling that PL2L60-expressing tumor nodules regressed three weeks later and then recurred soon with a comparable growth rate to GFP-transduced tumor cells. This might be the combined effects of the rapid growth and high susceptibility to innate anticancer immunity of the PL2L60-overexpressing tumor cells in SCID mice. However, PL2L60-overexpressing CSCs, like GFP-expressing CSCs, were resistant to innate immune cells, and thus be responsible for tumor recurrence. In contrast, GFP-transduced tumor cells are less proliferative and thus could not form tumor nodules at the latent phase. The hypothesis needs further verification. Taken together, PL2L60 expression can promote the tumorigenic capacity of tumor cells through promoting cell survival and proliferation in cooperation with NF-κB.

How does PL2L60 cooperate with NF-κB in modulating tumor development? It has been reported that Piwi proteins can promote euchromatin histone modifications and piRNA transcription in subtelomeric heterochromatin in Drosophila [15], [16]. The fact that co-expression of PL2L proteins with NF-κB exclusively in the euchromatin-enriched tumor cells suggests that PL2L60 could promote the functions of NF-κB through modulating chromatin structure or chromatin modifications [54], although precise mechanisms need to be elucidated further (Fig. 9).

Another important observation in this study is that in primary and metastatic cancers, nuclear PL2L proteins-expressing tumor cells are always co-expressed with nuclear NF-κB/p65 (nPL2L+p65+). Since nPL2L+p65+ cells were detected in various stages of breast cancers with individual variation in frequency (data not shown), quantitation of PL2L+p65+ cells in tumor tissues may predict the outcome of tumor progression or regression. It has been reported that NF-κB can bind the promoters of progression-associated genes in melanoma [47]; NF-κB has been shown to play important roles in tumor stem cells [45], [46]; and nuclear localization of NF-κB appears to be associated with the progression of prostate cancers [55]. Therefore, it is likely that the nuclear PL2L+p65+ tumor cells might represent tumor stem cells. Further characterization of nuclear PL2L+p65+ tumor cells is warranted for fully understanding of their relationship to tumor stem cell [4].

The broad goal of cancer research is to identify and characterize common developmental pathway for tumors, as it is critical for developing a safe and cost-effective therapeutic strategy for cancer [1], [3]. However, we are still far away from the goal. Although cancer genes have been extensively investigated for decades, most of them discovered so far are cancer-contributing genes, including oncogenes (ONGs), tumor suppressor genes (TSGs) and stability genes (SGs) rather than cancer-causing genes [56], [57]. These genes are converged to several signaling pathways, which are required as well for the normal control of cell survival and cell growth and thus dispensable for tumor development [57]. No cancer-causing gene has been identified so far [57]. An urgent need for cancer research community is to discover such kind of genes that are unique but common for the development of various types of cancer [3], [4], [57]. A cancer-causing gene should be silenced in normal adult cells but can be activated throughout the process of tumor initiation, progression and invasion without tissue restriction [1], [3], [4]. Like the ONG and TSG of cancer-contributing gene family [57], cancer-causing gene may be classified into tumor-barrier gene and tumor-initiating gene [3], [58]. Such kind of genes can override the function of cancer-contributing genes and their products can be used as common biomarkers for detection and intervention of cancers. Discovery of cancer-causing genes is currently a major challenge to cancer research [3], [4], [57]. Tumor stem cell (TSCs), which are supposed to undergo developmental process from tumor-initiating stem cells (TISCs) to pCSCs and CSCs [1], [3], [4], [59], are an ideal target for searching of cancer-causing genes, because their developing status is critical for tumor initiation, progression and invasion or metastasis [1], [3], [4]. Through the study of pCSCs, we have realized that Piwil2 and PL2L proteins might play important but distinct roles from ONGs, TSGs and SGs in tumor development. Piwil2 and PL2L proteins have the potential to serve as tumor-barrier gene and tumor-initiating gene, respectively [3]. Therefore, we propose that a cancer can develop from a lengthy process of benign proliferation → precancer → cancer, which is mediated by TISCs, pCSCs and CSCs, respectively; and the process might be controlled and/or modulated by Piwil2 and PL2L proteins. The functions of Piwil2 and PL2L proteins might override those of cancer-contributing genes. In addition to Piwil2 and PL2L proteins, other GSC and embryonic stem cell genes might be the potential candidates of cancer-causing genes [1], [3], [4], [59]. Should the hypothesis be proven, Piwil2 and PL2L proteins not only can be used as a common biomarker for tumor but also a target for the development of new anticancer drug.

Materials and Methods

Ethics Statement

Human specimens of cervical and breast cancer were remnant tissues derived from Tissue Archives material at Department of Pathology and provided by the Tissue Procurement Shared Resource (TPSR), Comprehensive Cancer Center, Ohio State University (OSU). The Archive material protocol, the informed consent and patient information forms were reviewed and approved by the Institutional Review Board (IRB), OSU. Each patient signed the consent form. The exemption protocol for this study was reviewed and approved by the Institutional Review Board (IRB), OSU (Protocol number: 2007EC686). Animal experiments were conducted based on Animal Use Protocols approved by the Institutional Animal Care and Use Committee (IACUC), OSU (Protocol number: 2006A0250).

Mice, cell lines, and reagents

Male C57BL/B6 (B6) mice, CB17 SCID mice and mili−/− B6 mice were used at the age of 8–12 wk. The mili−/− mice, which were obtained from Dr. Haifan Lin's laboratory [18], were bred and maintained in the animal pathogen-free facility at The Ohio State University Medical Center. The hematopoietic pCSC lines 2C4, 3B5C and 3B6C were cloned from a mouse with dendritic cell-like leukemia and characterized as previously described [5]. The hematopoietic CSC line (clone 326T) was developed in our laboratory ([1] & unpublished). EL-4 thymoma cells were maintained in our laboratory. Primary human dermal fibroblasts (HDFs) that were obtained from foreskin were obtained from Dr. Andrew Issekutz's laboratory. Cervical cancer cell line HeLa, breast cancer cell lines MD-MB-231, MD-MB-468, and MCF-7 were obtained from Dr. Sanford Barsky's laboratory, Other tumor or immortalized cell lines used in this study are listed in supplementary Table S2, which were obtained from Dr. Quansheng Zhou's laboratory except for where indicated. All the hematopoietic tumor cell lines were maintained in R10F (RPMI 1640 plus 10% fetal calf serum supplemented with 5 mM glutamine, 50 µM 2-mecaptoethonal, 100 U/ml penicillin, and 100 µg/ml streptomycin) [5], and non-hematopoietic tumor cell lines were maintained in D10F (Dulbecco's Modified Eagle Medium [DMEM] with the same supplements as in R10F) in our laboratory or co-author's laboratories for the cooperative experiments of this study. All cell lines were harvested at log phase of growth for RT-PCR or Western blot analysis.

RT-PCR

RT-PCR was performed as previously described [5], [6]. Total RNA was extracted from cell lines or de novo isolated testicular cells and splenocytes. The cDNA was generated by reverse transcription using Superscript II ( Invitrogen, CA) and oligo (dT) in a 20 µl reaction containing 1 µg of total RNA, which was pretreated with RNase-free DNase I (Invitrogen, CA) to eliminate contaminating genomic DNA. Briefly, an aliquot of 0.5 µl cDNA was used in each 20 µl PCR reaction, using PCR Master Mix (Promega, Ca). The following conditions were used: an initial denaturation at 95°C for 5 min followed by denaturation at 94°C for 30 seconds, annealing at 65°C for 1 min, touchdown −1°C per cycle, and extension at 72°C for 1 min for a total of 10 cycles. Then the condition was fixed for 25 cycles of denaturation at 94°C for 30 seconds, annealing at 50°C for 1 min, and extension at 72°C for 1 min with a final extension at 72°C for 10 min. PCR products were analyzed by 1.5% agarose gel. The sequence of primers is listed in the supplementary Table S1.

Gene-Exon-Mapping Reverse transcription polymerase chain reaction (GEM RT-PCR)

To identify Piwil2 variants, we designed four primer pairs specific for murine Piwil2 and three pairs for human PIWIL2, which cover the entire Piwil2 transcripts containing 23 exons of mice or humans and span the whole coding sequence. Each primer pair spanned at least one intron based on the databases of Ensembl (http://www.ensembl.org). The upstream of each pair of primers overlapped the downstream of previous one. The primers used for GEM RT-PCR are listed in supplementary Table S1. All primers were designed using PrimerQuest (http://www.idtdna.com/).

RNA interference (RNAi) Assay

RNAi assay was performed on murine pCSCs and human breast cancer cell lines, as previously described [5]. All siRNAs was purchased from the Integrated DNA Technologies (IDT, Coralville, IA). The murine pCSC cells were transfected with murine Piwil2-specific small interference (si) RNA (UCGUACCUACCGAAUCGAU), which targets exon 11 of Piwil2 within the open reading frame of PL2L60, or scrambled (sc) small RNA (scRNA) (CACGUGAGGAUCACCAUCA). The transfection was performed in 24-well plates with a siRNA transfection kit following the manufacturer's instruction (Qiagen). For the effect of Piwil2 exon 11-specific siRNA on cell expansion, a low density of transfected cells (100/well) was seeded and counted at indicated times. For RT-PCR analysis of PL2L60, a high density of transfected cells (1×106/well) was seeded and harvested at 36~48 h of culture and analyzed using primers specific for Piwil2 exon 6–14 (E6-14) and exon 18–21 (E18-21), respectively (Table S1). For RNAi experiments on human cancer cell lines, breast cancer cells MD-MB-231 were seeded overnight in triplicate at 2.5 – 3.0×105/well in 24-well plates and transfected with serum-free DMEM medium mixed with transfection reagents and 100 pmol human Piwil2 exon 21-specific dicer substrate RNA duplexes of 25 nucleotide in length (sense strand: 5′CUAUGAGAUUCCUCAACUACAGAAG; antisense strand: 5′ CUUCUGUAGUUGAGGAAUCUCAUAGUU), or universal negative control dicer-substrate duplex (DS Scrambled Neg) [60]. Transfection reagents and RNA duplexes were mixed and incubated in serum-free DMEM medium for 60 min before adding into culture plates.

Generation of rabbit polyclonal and murine monoclonal antibodies to Piwil2 and PL2L proteins

Polyclonal antibody to Piwil2 was generated in collaboration with Abgent Inc. Briefly, two New Zealand Rabbits were immunized each with 100~200 µg KLH-conjugated Piwil2 peptides (503 IPEKMKKDFRAMKDL 517) with a sequence common to humans and mice emulsified in the Complete Freund's Adjuvant (CFA) for twice in a two weeks interval, and then with 100 µg peptide/rabbit in the Incomplete Freund's Adjuvant (IFA) at week 4. Starting from week 5, the rabbits were immunized with 100 µg peptide/rabbit in PBS every week until week 9, and were bled for 20~30 ml every week until sacrificed at week 10. About 100 ml serum per rabbit was collected and rabbit IgG was purified by protein A/G chromatography followed by peptide-affinity chromatography. The titer and specificity of antibody was determined by competitive ELISA and Western-blot.

For generation of murine mAbs to Piwil2 and PL2L proteins, two BALB/c mice were immunized with the same peptide for rabbit polyclonal antibody in CFA, 100 µg per mouse, followed by boosting with 50 µg/mouse every week until the required titer was reached. Spleen cells from the mouse with best titer were fused with myeloma cell F0 by adding 1.5ml PEG 1500 per 3×108 mixed cells. Growing fused hybridoma clones were screened against antigen (such as free peptide) for test of their specificity and sensitivity. ELISA positive clones were tested by appropriate applications such as Western-blotting. Selected clones from this test were subcloned at least two times.

Western blot

Cell lysates and tissue extracts were mixed with equal volume of SDS-sample buffer (50 mM Tris-HCl, pH 7.4, 5 mMEDTA, 5% SDS, 20% glycerol, 10 mM DTT, 0.05% Bromophenol Blue) and heated at 95°C for 3 min. The proteins in samples were resolved on a 4~20% gradient Tris-glycine acrylamide gel and transferred to a nitrocellulose membrane. After blocking with 5% milk-TBS-Tween 20, immunoblotting was performed using either rabbit polyclonal anti-Piwil2 peptide antibody (IgG) or murine monoclonal anti-Piwil2 peptide antibody (IgM), or rabbit-anti-β-actin antibody. Following development with the appropriate species-specific horseradish peroxidase-conjugated anti-immunoglobulin antibodies and SuperSignal chemiluminescence substrate, the bands were visualized on X-ray film.

Construction of lentiviral PL2L60 vector (pLenti6-ZsGreen-PL2L60)

To construct the lentiviral expression vector expressing PL2L60, a pair of primers, 5′-GCG GAT CCA CCA TGG CTG ATG GGA AAG AGA TCA CAT TCT-3′ (sense) and 5′-GAG AAT TCA CAG GAA GAA CAG GTT CTC G-3′ (antisense), was used to amplify the cDNA coding for PL2L60 gene by PCR. The full-length human Piwil2 cDNA in plasmid pBluescriptR (cDNA clone MGC:26732 IMAGE:4826162) purchased from ATCC (Manassas, VA) was used as the template. The synthesized PL2L60 cDNA from PCR, which has a BamHI site in 5′ end and an EcoRI site in 3′ end derived from the primers, was cloned into the lentiviral vector pLenti6-ZsGreen, which is derived from a recombination of the Zoanthus sp. green fluorescent protein (ZsGreen) (Clontech) and pLenti6/V5-TOPO (Invitrogen), to generate pLenti6-ZsGreen-PL2L60. The insert of PL2L60 was verified by sequencing. Pseudotype pLenti6-ZsGreen-PL2L60 and pLenti6-ZsGreen viruses were produced by transfecting the 293FT cell line, as instructed by manufacturer (Invitrogen). The viral supernatants were harvested on 72 h post transfection.

Generation of stable cell lines overexpressing PL2L60

To generate cancer cell line overexpressing PL2L60, human breast cancer cell line MDA-MB-231 were transduced with lentiviral pLenti6-ZsGreen-PL2L60 (Lenti-PL2L60) or pLenti6-ZsGreen viruses (Lenti-GFP), as previously described [5]. Briefly, cells were seeded (2×105/ well) in 24-well plate in complete culture medium (D10F) and incubated overnight at 37°C in a humidified 5% CO2 incubator. Then, the medium was removed from the cultures and the Lenti-PL2L60 or Lenti-GFP viral supernatant was added. After overnight incubation, the medium containing viruses was replaced with fresh D10F. Fresh D10F containing 10 µg/ml of Blasticidin was added 24 h later to select stably transduced lines. The green fluorescent protein (GFP)-expressing cells from 231-PL2L60 and 231-GFP lines were sorted by flow cytometry, cloned by limiting dilution, and then maintained in D10F, respectively.

Cell cycle assay

Cell cycle analysis of tumor cell lines was performed as previously described with necessary modifications [61]. Briefly, tumor cell lines were cultured in D10F in the 6-well plates to about 80% confluence, washed with serum-free DMEM for twice, and continuously cultured in the serum-free medium for 16 h for cell starvation. Then, the cells were recovered by addition of D10F. Six hours later, the cells were harvested and washed with PBS, fixed in 70% ethanol (106 cells/ml), and stored at −20°C until being stained with propidium iodide (PI; 50 mg/ml) in PBS containing 1 mg/ml of glucose. The staining cells were incubated for 30 min at room temperature, and subjected to cell cycle analysis using flow cytometry. The acquired data were further analyzed using Modfit LT™ (Verity Software House).

Xenograft tumor transplantation

SCID CB17 mice were injected s.c. with 5×106 cloned 231-PL2L60 or 231-GFP cell lines. Tumor incidence and size were monitored once a week starting 1 wk after inoculation. Once tumors were palpable, tumor size was measured twice a week. The mice were sacrificed when one of the mice in any group developed a tumor about 15~20 mm in diameter. At the early stage of tumor formation and the end of experiments, living tumor images were taken using Macro Imaging System (LT-9MARCOIMSYS; Lightools Research).

Immunohistochemical (IHC) and immunocytochemical (ICC) analysis

IHC analysis of human tumor specimens was performed as previously described [5], [6], [32], [33], [62]. Tumor specimens of breast and cervical cancers were fixed in formalin and embedded in paraffin for pathological and immunohistochemical analysis, as described. Tissue microarrays (TMAs) were built by the Histological Core Facility, Department of Pathology. Serial TMA or conventional tissue sections (4~5 µm) were stained by H. & E. and a mouse mAb Kao1 (specific for Piwil2) or Kao2 (specific for Piwil2 and PL2L proteins) followed by a horseradish peroxidase (HRP)-conjugated secondary antibody for pathological and IHC analysis, respectively. The immunostained sections were counterstained with hematoxylin. In some experiments, TMA cores or conventional sections were double-stained with mouse mAb Kao2 (supernatant; 1[ratio]3 dilution) and rabbit mAb to RelA/p65 (1[ratio]100 dilution; Epitomics Inc.) in sequence. PL2L proteins (brown) were developed by the detection kit Envision plus Dual Link (Dako) and DAB chromogen, and p65 (pink) was revealed by the detection kit Mach 4 (Biocare) and Fast Red chromogen. For the double IHC staining control, serial sections were stained with a single primary antibody of interest.

For ICC analysis, the tumor cells growing at log phase were harvested, washed, and resuspended in 10% R10F (1–2×106 cells/ml). A mixture of 10 µl cell suspensions plus 190 µl PBS (1–2×104 cells/200 µl/slide) was subjected to cytospin at 1000 rpm for 3 minutes. The slides were air-dried, rehydrated and stained with rabbit mAb to p65, as described for IHC staining.

Statistical analysis

Data of multiple group observations were statistically analyzed by the one-way analysis of variance (ANOVA), and two groups of observations were compared by student-T test. A value of p≤0.05 was considered significant. Data are represented as mean ± SD. *, p≤0.05; **, p≤0.01.

Supporting Information

Figure S1

Piwil2 and PL2L genes are not expressed in normal tissues of mice.

(0.44 MB DOC)

Figure S2

PL2L60 was predominantly expressed in various types of tumor cell lines and some immortalized cell lines of humans and mice.

(1.22 MB DOC)

Figure S3

Generation of stable breast cancer cell lines overexpressing PL2L60.

(1.86 MB DOC)

Table S1

Primer sequences for RT-PCR.

(0.09 MB DOC)

Table S2

Tumor cell lines used in the study.

(0.11 MB DOC)

Acknowledgments

We thank Dr. Sergey Brodsky at the Department of Pathology for technical support. Dr. De-Tao Yin was a visiting scholar and partly supported by China Scholarship Council (CSC).

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: This work is supported from Strategy Initiative Grant (SIG) 2006/2007 (OSU Medical College), Immunology Program Award 2008 (OSUCCC) and American Cancer Society IRG-112367 (JXG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Gao JX. Cancer stem cells: the lessons from precancerous stem cells. J Cell Mol Med. 2008;12:67–96. [PubMed]
2. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, et al. Cancer Stem Cells—Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells. Cancer Res. 2006;66:9339–9344. [PubMed]
3. Gao J-X, Zhou Q. Epigenetic progenitors in tumor initiation and development. Drug Discovery Today: Disease Models. 2009;6:5–12.
4. Gao J-X. Development of Tumor Stem Cells: Implication in Field Cancerization. In: Dakubo G, editor. Field Cancerization: Basic Science and Clinical Applications. Hauppauge, NY: Novascience; 2010.
5. Chen L, Shen R, Ye Y, Pu XA, Liu X, et al. Precancerous Stem Cells Have the Potential for both Benign and Malignant Differentiation. PLoS ONE. 2007;2:e293. [PMC free article] [PubMed]
6. Shen R, Ye Y, Chen L, Yan Q, Barsky SH, et al. Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS ONE. 2008;3:e1652. [PMC free article] [PubMed]
7. Bussolati B, Grange C, Sapino A, Camussi G. Endothelial Cell Differentiation of Human Breast Tumor Stem/Progenitor Cells. J Cell Mol Med 2008 [PMC free article] [PubMed]
8. Damonte P, Hodgson JG, Chen J, Young L, Cardiff R, et al. Mammary carcinoma behavior is programmed in the precancer stem cell. Breast Cancer Research. 2008;10:R50. [PMC free article] [PubMed]
9. Hong D, Gupta R, Ancliff P, Atzberger A, Brown J, et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science. 2008;319:336–339. [PubMed]
10. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature. 2009;457:608–611. [PubMed]
11. Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, et al. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature. 2009;457:603–607. [PMC free article] [PubMed]
12. Becker L, Huang Q, Mashimo H. Immunostaining of Lgr5, an intestinal stem cell marker, in normal and premalignant human gastrointestinal tissue. ScientificWorldJournal. 2008;8:1168–1176. [PubMed]
13. Sasaki T, Shiohama A, Minoshima S, Shimizu N. Identification of eight members of the Argonaute family in the human genome small star, filled. Genomics. 2003;82:323–330. [PubMed]
14. Jaronczyk K, Carmichael JB, Hobman TC. Exploring the functions of RNA interference pathway proteins: some functions are more RISCy than others? Biochem J. 2005;387:561–571. [PubMed]
15. Yin H, Lin H. An epigenetic activation role of Piwi and a Piwi-associated piRNA in Drosophila melanogaster. Nature. 2007;450:304–308. [PubMed]
16. Sugimoto K, Kage H, Aki N, Sano A, Kitagawa H, et al. The induction of H3K9 methylation by PIWIL4 at the p16Ink4a locus. Biochemical and Biophysical Research Communications. 2007;359:497–502. [PubMed]
17. Cox DN, Chao A, Baker J, Chang L, Qiao D, et al. A novel class of evolutionarily conserved genes defined by piwi are essential for stem cell self-renewal. Genes Dev. 1998;12:3715–3727. [PubMed]
18. Kuramochi-Miyagawa S, Kimura T, Ijiri TW, Isobe T, Asada N, et al. Mili, a mammalian member of piwi family gene, is essential for spermatogenesis. Development. 2004;131:839–849. [PubMed]
19. Lee JH, Engel W, Nayernia K. Stem cell protein Piwil2 modulates expression of murine spermatogonial stem cell expressed genes. Mol Reprod Dev. 2006;73:173–179. [PubMed]
20. Deng W, Lin H. miwi, a murine homolog of piwi, encodes a cytoplasmic protein essential for spermatogenesis. Dev Cell. 2002;2:819–830. [PubMed]
21. Lee JH, Schutte D, Wulf G, Fuzesi L, Radzun HJ, et al. Stem-cell protein Piwil2 is widely expressed in tumors and inhibits apoptosis through activation of Stat3/Bcl-XL pathway. Hum Mol Genet. 2006;15:201–211. [PubMed]
22. Kuramochi-Miyagawa S, Kimura T, Yomogida K, Kuroiwa A, Tadokoro Y, et al. Two mouse piwi-related genes: miwi and mili. Mech Dev. 2001;108:121–133. [PubMed]
23. Carmell MA, Xuan Z, Zhang MQ, Hannon GJ. The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis. Genes Dev. 2002;16:2733–2742. [PubMed]
24. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science. 2004;305:1437–1441. [PubMed]
25. Dawe RK. RNA interference on chromosomes. Nat Genet. 2004;36:1141–1142. [PubMed]
26. Folco HD, Pidoux AL, Urano T, Allshire RC. Heterochromatin and RNAi Are Required to Establish CENP-A Chromatin at Centromeres. Science. 2008;319:94–97. [PMC free article] [PubMed]
27. Tomari Y, Du T, Zamore PD. Sorting of Drosophila Small Silencing RNAs. Cell. 2007;130:299–308. [PMC free article] [PubMed]
28. Preall JB, Sontheimer EJ. RNAi: RISC Gets Loaded. Cell. 2005;123:543–545. [PubMed]
29. Tahbaz N, Kolb FA, Zhang H, Jaronczyk K, Filipowicz W, et al. Characterization of the interactions between mammalian PAZ PIWI domain proteins and Dicer. EMBO Rep. 2004;5:189–194. [PubMed]
30. Rand TA, Ginalski K, Grishin NV, Wang X. Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:14385–14389. [PubMed]
31. Buhler M, Verdel A, Moazed D. Tethering RITS to a nascent transcript initiates RNAi- and heterochromatin-dependent gene silencing. Cell. 2006;125:873–886. [PubMed]
32. Liu JSR, Gang H, Chen L, Yin Y, Hua K, Jarjoura D, Nakano T, Ramesh GK, Shapiro CL, Barsky SH, Gao JX. Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker. Int J Clin Exp Pathol. 2010;3:328–337. [PMC free article] [PubMed]
33. He G, Chen L, Ye Y, Xiao Y, Hua K, et al. Piwil2 expressed in various stages of cervical neoplasia is a potential complementary marker for p16INK4a. Am J Transl Res. 2010;2:156–169. [PMC free article] [PubMed]
34. Feng DQ, Peng C, Li CR, Zhou Y, Li M, et al. Identification and characterization of cancer stem-like cells from primary carcinoma of the cervix uteri. Oncology Reports. 2009;22:1129–1134. [PubMed]
35. Lee JH, Jung C, Javadian-Elyaderani P, Schweyer S, Schütte D, et al. Pathways of Proliferation and Antiapoptosis Driven in Breast Cancer Stem Cells by Stem Cell Protein Piwil2. Cancer Research. 2010;70:4569–4579. [PubMed]
36. Qiao D, Zeeman AM, Deng W, Looijenga LH, Lin H. Molecular characterization of hiwi, a human member of the piwi gene family whose overexpression is correlated to seminomas. Oncogene. 2002;21:3988–3999. [PubMed]
37. Li L, Yu C, Gao H, Li Y. Argonaute proteins: potential biomarkers for human colon cancer. BMC Cancer. 2010;10:38. [PMC free article] [PubMed]
38. Aravin A, Gaidatzis D, Pfeffer S, Lagos-Quintana M, Landgraf P, et al. A novel class of small RNAs bind to MILI protein in mouse testes. Nature. 2006;442:203–207. [PubMed]
39. Aravin AA, Sachidanandam R, Girard A, Fejes-Toth K, Hannon GJ. Developmentally regulated piRNA clusters implicate MILI in transposon control. Science. 2007;316:744–747. [PubMed]
40. Grivna ST, Beyret E, Wang Z, Lin H. A novel class of small RNAs in mouse spermatogenic cells. Genes Dev. 2006;20:1709–1714. [PubMed]
41. Grivna ST, Pyhtila B, Lin H. MIWI associates with translational machinery and PIWI-interacting RNAs (piRNAs) in regulating spermatogenesis. Proc Natl Acad Sci U S A. 2006;103:13415–13420. [PubMed]
42. Lau NC, Seto AG, Kim J, Kuramochi-Miyagawa S, Nakano T, et al. Characterization of the piRNA complex from rat testes. Science. 2006;313:363–367. [PubMed]
43. Saito K, Nishida KM, Mori T, Kawamura Y, Miyoshi K, et al. Specific association of Piwi with rasiRNAs derived from retrotransposon and heterochromatic regions in the Drosophila genome. Genes Dev. 2006;20:2214–2222. [PubMed]
44. Brennecke J, Aravin AA, Stark A, Dus M, Kellis M, et al. Discrete small RNA-generating loci as master regulators of transposon activity in Drosophila. Cell. 2007;128:1089–1103. [PubMed]
45. Dreesen O, Brivanlou A. Signaling Pathways in Cancer and Embryonic Stem Cells. Stem Cell Reviews and Reports. 2007;3:7–17. [PubMed]
46. Grandage VL, Gale RE, Linch DC, Khwaja A. PI3-kinase//Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-κB, MAPkinase and p53 pathways. Leukemia. 2005;19:586–594. [PubMed]
47. Ryu B, Kim DS, DeLuca AM, Alani RM. Comprehensive Expression Profiling of Tumor Cell Lines Identifies Molecular Signatures of Melanoma Progression. PLoS ONE. 2007;2:e594. [PMC free article] [PubMed]
48. Melcher R, Steinlein C, Feichtinger W, Muller CR, Menzel T, et al. Spectral karyotyping of the human colon cancer cell lines SW480 and SW620. Cytogenet Cell Genet. 2000;88:145–152. [PubMed]
49. He G, Chen L, Ye Y, Xiao Y, Hua K, et al. Piwil2 expressed in various stages of cervical neoplasia is a potential complementary marker for p16. Am J Transl Res. 2010;2:156–169. [PMC free article] [PubMed]
50. Liu JSR, Gang H, Chen L, Yin Y, Hua K, Jarjoura D, Nakano T, Ramesh GK, Shapiro CL, Barsky SH, Gao JX. Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker. Int J Clin Exp Pathol. 2010;3:10. [PMC free article] [PubMed]
51. Nikpour P, Forouzandeh-Moghaddam M, Ziaee SA, Dokun OY, Schulz WA, et al. Absence of PIWIL2 (HILI) expression in human bladder cancer cell lines and tissues. Cancer Epidemiol. 2009;33:271–275. [PubMed]
52. Chiu C-C, Chen JY-F, Lin K-L, Huang C-J, Lee J-C, et al. p38 MAPK and NF-κB pathways are involved in naphtho[1,2-b] furan-4,5-dione induced anti-proliferation and apoptosis of human hepatoma cells. Corrected Proof. In Press. [PubMed]
53. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–3988. [PubMed]
54. Wang J, Jacob NK, Ladner KJ, Beg A, Perko JD, et al. RelA/p65 functions to maintain cellular senescence by regulating genomic stability and DNA repair. EMBO Rep. 2009;10:1272–1278. [PubMed]
55. Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer. 2005;93:1019–1023. [PMC free article] [PubMed]
56. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458:719–724. [PMC free article] [PubMed]
57. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789–799. [PubMed]
58. Mader RM. Disease models in cancer. Drug Discovery Today: Disease Models. 2009;6:1–3.
59. Werbowetski-Ogilvie TE, Bhatia M. Pluripotent human stem cell lines: what we can learn about cancer initiation. Trends in Molecular Medicine. 2008;14:323–332. [PubMed]
60. Kim D-H, Behlke MA, Rose SD, Chang M-S, Choi S, et al. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotech. 2005;23:222–226. [PubMed]
61. Gao JX, Zhang J, Awaraji C, Bhatia M, Jevnikar A, et al. Preferential proliferation and differentiation of double-positive thymocytes into CD8(+) single-positive thymocytes in a novel cell culture medium. Cell Immunol. 2000;202:41–53. [PubMed]
62. Gao JX, Liu X, Wen J, Zhang H, Durbin J, et al. Differentiation of Monocytic Cell Clones into CD8alpha(+) Dendritic Cells (DC) Suggests that Monocytes Can Be Direct Precursors for Both CD8alpha(+) and CD8alpha(-) DC in the Mouse. J Immunol. 2003;170:5927–5935. [PubMed]
63. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. JExpMed. 1992;176:1693–1702. [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science